The most critical failure in clinical research isn't a failed molecule. It's an empty chair. For years, the industry's primary method for finding patients for trials has been a slow, site-dependent process that leaves roughly 80% of studies delayed due to recruitment problems. The human cost is measured in years of waiting for new treatments. In 2015, Clara Health began with a simple, patient-focused premise: what if finding a trial was as straightforward as using a modern consumer app?
Clara positioned itself as a technology-driven clinical research organization (CRO). Its core bet was that a digital, patient-centric platform could act as a more effective intermediary than traditional methods. The company built software and services to help patients navigate and connect with clinical trials, while providing sponsors and CROs with tools to recruit and retain those participants [ZoomInfo, Unknown]. The analogy, used in early coverage, was apt: a "Match.com for patients and experimental treatments" [Forbes, 2017-11-16].
The Wedge of Patient Navigation
Clara's product wedge was distinct from pure software vendors. It combined a patient-facing matching service with dedicated human support, assigning a unique study team to each client [guides.clarahealth.com, Unknown]. This aimed to address the full funnel, from initial awareness through screening to ongoing participation. The value proposition to pharmaceutical and biotech sponsors was clear: improved speed and, crucially, better diversity in enrollment by reaching patients directly online, beyond the geographic and demographic limits of individual trial sites [PrivCo, Unknown].
For patients, often navigating a complex and frightening diagnosis, the promise was a guided path. Instead of scouring clinicaltrials.gov alone, they could use Clara's platform to find potential trials and receive support through the eligibility and consent process. The company claimed this approach reduced patient drop-off and lessened the administrative burden on trial sites [ZoomInfo, Unknown].
A Young Team With Institutional Backing
The founders, Evan Ehrenberg and Sol Chen, were notably young when they started Clara Health. Both were featured in the Forbes 30 Under 30 list in 2018, Ehrenberg at 24 and Chen at 22 [Forbes, 2017-11-16]. Their backgrounds suggested a blend of deep technical and scientific rigor with product-building focus. Ehrenberg graduated from UC Berkeley at 16 and later managed AI research at institutions including MIT and Palantir [Newsweek Expert Forum, Unknown]. Chen brought a background in mathematics, economics, and computer science from Brown University [me.sh, Unknown].
Their venture attracted serious institutional capital, a signal of belief in the patient-recruitment bottleneck as a venture-scale problem. The company raised approximately $18.2 million across five funding rounds, according to financial aggregators [TheCompanyCheck, Unknown]. A Series A round of $11 million was completed in April 2020 [TheCompanyCheck, Unknown]. The investor list included names like Founders Fund, Khosla Ventures, and the Thiel Foundation, backers known for supporting foundational technology bets [TheCompanyCheck, Unknown].
| Founder | Role | Key Background |
|---|---|---|
| Evan Ehrenberg | Co-Founder, CEO | Neuroscience research, AI management at MIT & Palantir [Newsweek Expert Forum, Unknown] |
| Sol Chen | Co-Founder, CTO | B.S. from Brown University in math, economics, and computer science [me.sh, Unknown] |
The Competitive and Regulatory Landscape
Clara Health operated in a crowded but critical space. It competed with other tech-enabled patient recruitment and trial management platforms like Reify Health and VitalTrax. The broader competitive set included legacy CROs and site networks. Clara's differentiation rested on its integrated model of software plus concierge-style support, aiming to own the patient relationship from discovery forward.
The regulatory context was always present. Any platform involved in patient screening and referral operates within the strict frameworks of HIPAA and clinical trial regulations governed by the FDA. Success required not just elegant software, but robust compliance protocols and trust from institutional review boards. For sponsors, the ultimate proof point was not user engagement, but the delivery of qualified, consenting patients who remained in the study.
The Acquisition and the Road Not Taken
The company's independent journey concluded on March 9, 2022, when it was acquired by M&B Sciences [Mergr, 2022-03-09]. The acquisition terms were not disclosed. For a venture-backed startup, an acquisition is a clear validation of its technology and team, but it also closes the book on its potential to become a standalone, category-defining giant. In Clara's case, being absorbed into a larger clinical research entity suggests its tools were seen as valuable components for a broader service offering, rather than as a disruptive platform that would rewire the industry on its own.
The risks Clara faced were substantial, even beyond the typical startup challenges.
- The two-sided marketplace challenge. The model required simultaneously attracting a critical mass of patients and convincing sponsors to pay for access to them. A slow start on either side could stall the entire engine.
- The cost of care. Providing personalized, human support to patients is inherently unscalable and expensive. The economics of blending high-touch service with software margins had to be proven at scale.
- Data fragmentation. Patient health data is siloed across thousands of health systems. Without deep electronic health record (EHR) integrations, pre-screening patients accurately remains a significant hurdle.
Clara's most plausible answer to these challenges was its hybrid approach. By not being a pure software play, it could guarantee a higher quality of patient referral, justifying its cost to sponsors. The dedicated study teams were a cost center, but also a potential moat against lighter-weight software competitors.
What the Standard of Care Looks Like
For patients with serious conditions like metastatic cancer, advanced heart failure, or rare genetic disorders, the standard of care for finding a clinical trial remains fragmented and arduous. It typically relies on a patient's own oncologist or specialist having awareness of an open trial at their institution. If not, the search falls to the patient or family to comb through databases, make countless phone calls, and navigate complex eligibility criteria alone. The process is time-consuming, emotionally draining, and often ends in dead ends due to geography or strict protocol requirements.
Clara Health aimed to be the navigator for that population. Its acquisition by M&B Sciences means its technology and methodology continue to operate, albeit within a larger corporate structure. The fundamental problem it tackled,connecting the right patient to the right trial at the right time,remains one of the most persistent bottlenecks in delivering new medicines. The company's seven-year run proved there is venture-scale value in trying to solve it, even if the definitive, platform-level solution is still being built.
Sources
- [Forbes, 2017-11-16] Sol Chen, 22 (L) Evan Ehrenberg, 24 - 2018 30 Under 30: Healthcare | https://www.forbes.com/pictures/5a01049631358e542c04dcf6/sol-chen-22-l-evan-ehrenb/
- [guides.clarahealth.com, Unknown] Clara Health service description | https://guides.clarahealth.com
- [Mergr, 2022-03-09] Clara Health acquired by M&B Sciences | https://www.crunchbase.com/acquisition/m-b-sciences-acquires-clarahealth--faf783c8
- [Newsweek Expert Forum, Unknown] Evan Ehrenberg background | https://www.newsweek.com
- [PrivCo, Unknown] Clara Health Care company profile | https://www.privco.com/company/clara-health-care
- [TheCompanyCheck, Unknown] Clara Health funding and investors | https://www.thecompanycheck.com/company/b/clara-health/klqhha4288mel4yw0
- [ZoomInfo, Unknown] Clara Health company overview | https://www.zoominfo.com/c/clara-health/449805192
- [me.sh, Unknown] Sol Chen background | https://me.sh